Landscape Capital Management L.L.C. Takes Position in Indivior PLC (NASDAQ:INDV)

Landscape Capital Management L.L.C. bought a new stake in Indivior PLC (NASDAQ:INDV) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 78,682 shares of the company’s stock, valued at approximately $978,000. Landscape Capital Management L.L.C. owned about 0.06% of Indivior at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of INDV. Kazazian Asset Management LLC bought a new stake in Indivior during the 4th quarter valued at $1,706,000. Amundi lifted its holdings in shares of Indivior by 12.2% during the fourth quarter. Amundi now owns 174,434 shares of the company’s stock valued at $2,109,000 after purchasing an additional 19,010 shares during the last quarter. Clark Estates Inc. NY raised its stake in Indivior by 1.3% during the fourth quarter. Clark Estates Inc. NY now owns 257,400 shares of the company’s stock valued at $3,199,000 after buying an additional 3,300 shares during the last quarter. VELA Investment Management LLC raised its position in shares of Indivior by 45.5% in the 4th quarter. VELA Investment Management LLC now owns 179,659 shares of the company’s stock worth $2,264,000 after purchasing an additional 56,224 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Indivior during the 4th quarter valued at about $56,000. Institutional investors own 60.33% of the company’s stock.

Indivior Stock Down 2.5 %

Shares of INDV opened at $9.15 on Friday. The business has a 50-day simple moving average of $9.98 and a two-hundred day simple moving average of $10.37. Indivior PLC has a 52 week low of $7.33 and a 52 week high of $21.64. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -26.14 and a beta of 0.93.

Indivior (NASDAQ:INDV) last released its earnings results on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.32. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The company had revenue of $298.00 million during the quarter, compared to analyst estimates of $262.35 million. On average, equities analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on INDV. Rodman & Renshaw began coverage on shares of Indivior in a report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 target price on the stock. Piper Sandler reduced their price target on shares of Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a research report on Thursday, March 6th. Finally, RODMAN&RENSHAW raised shares of Indivior to a “strong-buy” rating in a report on Tuesday, January 28th.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.